BioTime is also developing HyStem ® for the delivery of therapeutic drugs and cells to localized areas of the body, including for sustained drug release in the targeted anatomical sites. BioTime’s ...
Greetings and welcome to the BioTime Second Quarter 2017 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to introduce your host for ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results